Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

Summary

The purpose of this study is to prove the superiority of a 48-weeks treatment with budesonide orodispersible tablets versus placebo for the maintenance of clinico-pathological remission in patients with eosinophilic esophagitis.

Timeline

Start

2016-01-15

Primary completion

2018-11-28

Completion

2020-12-11

Publications

• Biedermann L, Schlag C, Straumann A, Lucendo AJ, Miehlke S, Vieth M, Santander C, Ciriza de Los Rios C, Schmocker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Halstead M, Pfurr S, Mueller R, Schoepfer AM, Attwood S; International EOS-2 Study Group. Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study. Clin Gastroenterol Hepatol. 2025 Nov;23(12):2144-2154.e6. doi: 10.1016/j.cgh.2024.10.034. Epub 2024 Dec 16.

Drugs

Indications